Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Basit Öğe Kaydı
dc.authorid0000-0003-4629-6815en_US
dc.authorid0000-0001-6980-2800en_US
dc.contributor.authorYekedüz, Emre
dc.contributor.authorÖzbay, Mehmet Fatih
dc.contributor.authorÇağlayan, Dilek
dc.contributor.authorYıldırım, Atila
dc.contributor.authorErol, Cihan
dc.contributor.authorYıldırım, Hasan Çağrı
dc.contributor.authorTunç, Sezai
dc.contributor.authorÖzyurt, Neslihan
dc.contributor.authorÖzdemir, Feyyaz
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2024-03-20T08:37:01Z
dc.date.available2024-03-20T08:37:01Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractAim: To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and non-user patients with metastatic colorectal cancer (mCRC) treated with regorafenib. Methods: We included 272 patients with mCRC treated with regorafenib in this study. Patients were divided into two categories according to their status of PPI use. The primary endpoint was overall survival (OS). The secondary endpoints were time to treatment failure (TTF), response rates, and safety. To exclude immortal time bias in survival analyses, we compared PPI non-user patients and all patients. Results: There were 141 and 131 patients in the PPI non-user and user groups. Baseline characteristics were similar in each group. Pantoprazole was the most used PPI. At the median 35.2 (95% confidence interval (CI): 32.6–37.9) months follow-up, the median OS was similar in PPI non-user and all patients (6.9 months (95% CI: 5.3–8.5) and 7.7 months (95% CI:6.6–8.8), p = 0.913). TTF was also similar in PPI non-user and all patients (3.3 months (95% CI: 2.7–3.9) and 3.5 months (95% CI: 3.0–4.0), p = 0.661). In multivariable analysis, no statistically significant difference was observed between PPI user and non-user groups in OS and TTF (hazard ratio (HR), 0.99; 95% CI, 0.77–1.28; p = 0.963 for OS; HR, 0.93; 0.77–1.20, p = 0.598 for TTF). The objective response rates (ORR) were similar in the PPI non-user and user groups (19.8% and 16.8%, p = 0.455). The rates of any grade AEs were also similar in each group. Conclusion: This study found no worse outcome in the combined use of PPI and regorafenib among patients with mCRC.en_US
dc.identifier.citationYekedüz, E., Özbay, M. F., Çağlayan, D., Yıldırım, A., Erol, C., Yıldırım, H. Ç. ve diğerleri. (2022). Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study. European Journal of Clinical Pharmacology, 78(12), 1973-1979.en_US
dc.identifier.doi10.1007/s00228-022-03403-1
dc.identifier.endpage1979en_US
dc.identifier.issn0031-6970
dc.identifier.issue12en_US
dc.identifier.pmid36266366
dc.identifier.scopus2-s2.0-85140336938
dc.identifier.scopusqualityQ2
dc.identifier.startpage1973en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s00228-022-03403-1
dc.identifier.urihttps://hdl.handle.net/11468/13650
dc.identifier.volume78en_US
dc.identifier.wosWOS:000870609400001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTunç, Sezai
dc.institutionauthorIşıkdoğan, Abdurrahman
dc.language.isoenen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.relation.ispartofEuropean Journal of Clinical Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcid suppressionen_US
dc.subjectDrug-drug interactionsen_US
dc.subjectRegorafeniben_US
dc.titleClinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter studyen_US
dc.titleClinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer_ a multicenter study.pdf
Boyut:
868.14 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu